Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Parkinson Disease, Tremor
Interventions: Placebo, Suvecaltamide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 18 more

Conditions: CD20+ Follicular Lymphoma
Interventions: Duvelisib, Rituximab, Obinutuzumab; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • Hackensack, New Jersey + 2 more

Conditions: Pelvic Pain, Endometriosis
Interventions: Metformin Hydrochloride, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: Artesunate; Drug
Lead sponsor: Joseph C. Wu; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neimann-Pick Disease
Interventions: Vorinostat; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anxiety Disorders
Interventions: SSR149415, Placebo, Paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bipolar Depression
Interventions: cariprazine, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Encino, California • Garden Grove, California • National City, California + 23 more

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Advanced Solid Tumors
Interventions: axitinib, crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 15
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Colorectal Cancer Metastatic, mCRC
Interventions: Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT; Biological · Drug · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Diabetes Mellitus, Type 2, Diastolic Dysfunction
Interventions: LCZ 696, Placebos; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cannabis Use Disorder
Interventions: THC, Alprazolam, Placebo oral capsule, CBD; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Obstructive Sleep Apnea
Interventions: AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more

Conditions: Hypogonadotropic Hypogonadism
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more

Conditions: Depression
Interventions: Psilocybin, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham taVNS; Drug · Device
Lead sponsor: Charles Raison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Healthy
Interventions: Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 60 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Davis, California

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more

Conditions: Eye Strain, Eye Fatigue
Interventions: Blackcurrant, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions: Colchicine, Diltiazem ER; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypothyroidism
Interventions: Armour Thyroid, Levothyroxine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 134
States / cities: Birmingham, Alabama • Bonita, California • Burbank, California + 110 more

Conditions: Hepatitis C Virus Infection
Interventions: Simeprevir, Sofosbuvir; Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 38
States / cities: Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more

Conditions: HIV Infections
Interventions: Truvada, Atazanavir, Ritonavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Foster City, California

Search by objective public record fields.

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Glycemic Regulation as Endometriosis Adjunct Treatment

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

Crossover Trial of AD109 in Obstructive Sleep Apnea

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Investigation to Understand and Optimize Psilocybin

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

The Effects of Blackcurrant Supplementation on Eye Health

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study